抑制硬脂酰辅酶A去饱和酶对高水平从头脂肪酸生物合成与去饱和的急性髓系白血病具有毒性
研究鉴定硬脂酰辅酶A去饱和酶(SCD)为急性髓系白血病(AML)预后相关指标,使用临床级抑制剂SSI-4在体外和体内多种AML模型中证实SCD抑制(SCDi)是治疗脆弱点。SCDi引起脂毒性,通过多效作用诱导AML细胞死亡,敏感性 correlates with AML对脂肪酸去饱和的依赖,不受突变谱影响,并受脂肪酸生物合成活性调节。脂毒性增加化疗诱导的DNA损伤,标准化疗进一步增敏AML细胞对SCDi。
要点
- SCD是脂肪酸去饱和的关键酶,其表达与AML患者预后相关
- 临床级抑制剂SSI-4在体外和体内多种AML模型中显示SCDi具有治疗脆弱性
- SCDi通过脂毒性多效作用诱导AML细胞死亡,敏感性受脂肪酸生物合成活性调节
核心结论
- SCD抑制在多种AML模型中显示治疗脆弱性,支持开发脂肪酸去饱和酶抑制剂用于AML,同时强调需识别预测性生物标志物和生物学验证的联合治疗以充分发挥治疗潜力。
研究设计与样本
- 研究使用临床级抑制剂SSI-4在体外和体内多种AML模型中进行,并进行多组学分析。
主要发现
- SCDi引起脂毒性,通过多效作用诱导AML细胞死亡。
- 对SCDi的敏感性与AML对脂肪酸去饱和的依赖相关,不受突变谱影响,并受脂肪酸生物合成活性调节。
- 脂毒性增加化疗诱导的DNA损伤,标准化疗进一步增敏AML细胞对SCDi。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Identification of specific and therapeutically actionable vulnerabilities, ideally present across multiple mutational backgrounds, is needed to improve acute myeloid leukemia (AML) patients' outcomes. We identify stearoyl-CoA desaturase (SCD), the key enzyme in fatty acid (FA) desaturation, as prognostic of patients' outcomes and, using the clinical-grade inhibitor SSI-4, show that SCD inhibition (SCDi) is a therapeutic vulnerability across multiple AML models in vitro and in vivo. Multiomic analysis demonstrates that SCDi causes lipotoxicity, which induces AML cell death via pleiotropic effects. Sensitivity to SCDi correlates with AML dependency on FA desaturation regardless of mutational profile and is modulated by FA biosynthesis activity. Finally, we show that lipotoxicity increases chemotherapy-induced DNA damage and standard chemotherapy further sensitizes AML cells to SCDi. Our work supports developing FA desaturase inhibitors in AML while stressing the importance of identifying predictive biomarkers of response and biologically validated combination therapies to realize their full therapeutic potential.
引用
- Dembitz V, Lawson H, Burt R, et al. Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation. Leukemia. 2024. PMID: 39187579. doi:10.1038/s41375-024-02390-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。